What were the findings of the Costa Rica Vaccine Trial regarding the efficacy of human papillomavirus (HPV) vaccination?

Updated: Feb 12, 2019
  • Author: Cecelia H Boardman, MD; Chief Editor: Warner K Huh, MD  more...
  • Print

In the Costa Rica Vaccine Trial, researchers documented durable antibody responses after 1 dose (as opposed to the standard 3 doses) of the bivalent human papillomavirus (HPV) 16/18 L1 viruslike particle vaccine Cervarix. [101, 102] The investigators evaluated 78 women who received 1 dose of the vaccine, 192 who received 2 doses, and 120 who received all 3 doses. These women were compared with 113 women who did not receive vaccine but had antibodies against the viruses. All subjects in the 3 vaccine groups had antibodies against HPV 16 and 18 for as long as 4 years. [102] Although antibody titers in women who received 1 dose were lower than those in women who received 3 doses, they remained stable over 4 years.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!